8-K: Forte Biosciences Reports Positive Phase 1b Vitiligo Study Results

Forte Biosciences announced positive top-line results from its Phase 1b study of FB102 in vitiligo, showing statistically significant improvements in facial skin depigmentation.

Summary

• Forte Biosciences announced positive results from its double-blind, placebo-controlled Phase 1b study of FB102 for the treatment of vitiligo.
• The study met its primary endpoint, demonstrating a statistically significant mean FVASI (Facial Vitiligo Area and Severity Index) improvement from baseline at week 24.
• FB102-treated subjects showed a 29.6% mean FVASI improvement compared to a deterioration of 16.2% in the placebo group, resulting in a placebo-adjusted benefit of 45.8% (p=0.005) in the intent-to-treat (ITT) population.
• In the protocol-defined efficacy-evaluable population, FB102 achieved a 29.6% mean FVASI improvement versus 7.9% for placebo, a placebo-adjusted benefit of 21.7% (p=0.020).
• Statistically significant improvements were observed as early as day 64 and continued through week 24, even after the 12-week treatment period concluded.
• Subjects with greater baseline disease involvement (FVASI >= 0.75) showed a mean FVASI improvement of 43.2% at week 24 (p=0.006).
• Responder analysis indicated that 34.4% of FB102-treated subjects achieved FVASI50 and 12.5% achieved FVASI75 at week 24 in the efficacy-evaluable population.
• In subjects with baseline FVASI >= 0.75, 58.8% achieved FVASI50 and 23.5% achieved FVASI75.
• A significant majority of FB102-treated subjects (84%) improved from baseline by week 24, with none worsening, while 27% of placebo subjects worsened.
• FB102 demonstrated a strong safety profile with only mild to moderate adverse events, comparing favorably to placebo.
• The company will host a conference call on July 9, 2026, at 8:30 a.m. ET to discuss the study results.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, with statistically significant clinical results and a strong safety profile, indicating strong potential for FB102.

Positives

• Statistically significant mean FVASI improvement of 29.6% from baseline at week 24 in the ITT population (p=0.005).
• Early onset of response observed by day 64, with statistically significant improvements continuing through week 24.
• Stronger response in subjects with greater disease involvement (FVASI >= 0.75), achieving 43.2% mean FVASI improvement at week 24 (p=0.006).
• Positive responder rates: 34.4% achieved FVASI50 and 12.5% achieved FVASI75 in the efficacy-evaluable population.
• High proportion of treated subjects improved (84%) with no worsening, compared to 27% worsening in the placebo group.
• FB102 demonstrated a strong and favorable safety profile with only mild to moderate adverse events.
• The drug's mechanism of action, modulating IL-2 and IL-15 dependent pathogenic T-cell biology while preserving regulatory T cells, is supported by the data.
• The results in vitiligo, combined with prior Phase 1b activity in celiac disease, reinforce the broad potential of FB102.

Negatives

• One placebo subject in the efficacy-evaluable population experienced worsening of vitiligo, which impacted responder endpoint interpretation.
• While statistically significant, the overall FVASI improvement percentages may be considered moderate by some standards, especially in the context of a Phase 1b study.
• The study design involved a 12-week treatment period followed by observation, and the continued improvement through week 24 might not be indicative of long-term sustained efficacy without further treatment.

Risks

• The company cautions that actual results and the timing of events could differ materially from forward-looking statements due to various risks and uncertainties.
• Risks include the ability to obtain sufficient additional capital to advance FB102.
• Uncertainties associated with clinical development and regulatory approval of FB102, including potential delays in trial commencement, enrollment, and completion.
• The risk that results from preclinical and interim clinical trials may not be predictive of future results.
• The risk that the ongoing Phase 2 celiac disease trial will not produce similar results despite positive Phase 1b data.
• Failure to realize any value from FB102 due to inherent risks, expenses, and difficulties in bringing product candidates to market.
• The company's ability to protect its intellectual property position.
• The impact of global events on the company, its industry, or the economy generally.

Future Outlook

The company anticipates the imminent readout from its ongoing Phase 2 celiac disease trial as the next important clinical catalyst for FB102. The company's optimized FB102 blockade of CD122 is designed to modulate IL-2 and IL-15 dependent pathogenic T-cell biology while preserving regulatory T cells, with clinical data supporting this profile. This approach may enable broader immune pathway modulation than IL-15 blockade alone and avoid regulatory T-cell modulation associated with overly potent CD122 inhibition.

Management Comments

• "With statistically significant placebo-controlled activity now demonstrated in vitiligo and the prior Phase 1b activity demonstrated in celiac disease, we look forward to the imminent readout from our ongoing Phase 2 celiac disease trial as the next important clinical catalyst for FB102," said Paul Wagner, PhD, Chairman and CEO of Forte Biosciences.
• "Fortes optimized FB102 blockade of CD122 was designed to modulate both IL-2 and IL-15dependent pathogenic T-cell biology while preserving regulatory T cells, and clinical data to date support this profile."
• "This may enable broader immune pathway modulation than IL-15 blockade alone and may avoid the regulatory T-cell modulation that can occur with overly potent CD122 inhibition."
• "Data from this Phase 1b vitiligo study and from the previously reported Phase 1b trial in celiac disease reinforce the activity and broad potential for FB102."

Industry Context

StockSavvy.ai notes that the positive results for FB102 in vitiligo are significant given the substantial unmet need in this autoimmune skin condition. The company's approach of modulating IL-2 and IL-15 pathways, while preserving regulatory T cells, offers a potentially differentiated mechanism compared to other therapies, particularly in light of regulatory scrutiny on JAK inhibitors.

Comparison to Industry Standards

• The filing presents FVASI50 and FVASI75 data at week 24, comparing them to Phase 2 data from other studies (Passeron T, et al. eClinicalMedicine. 2024; Pandya AG, et al. J Am Acad Dermatol. 2025; Ezzedine K, et al. J Am Acad Dermatol. 2023).
• In the FB102 study, FVASI50 was achieved by 34.4% of subjects in the efficacy-evaluable population and 58.8% in subjects with baseline FVASI >= 0.75.
• FVASI75 was achieved by 12.5% of subjects in the efficacy-evaluable population and 23.5% in subjects with baseline FVASI >= 0.75.
• The filing implies that these results are competitive, particularly for subjects with more severe disease, but specific numerical comparisons to the cited competitor studies are not detailed within the provided text.

Stakeholder Impact

• Shareholders: Positive results are likely to be viewed favorably, potentially impacting stock price and investor confidence.
• Patients with Vitiligo: The positive results offer hope for a new, effective, and safe treatment option.
• Medical Community: The data supports FB102's potential as a therapeutic agent for vitiligo and other autoimmune diseases.

Next Steps

• Forte will be hosting a conference call to discuss the study results.
• The company looks forward to the imminent readout from its ongoing Phase 2 celiac disease trial as the next important clinical catalyst for FB102.

Key Dates

Recommendation

While the Phase 1b results are positive and statistically significant, they represent early-stage data. Further validation in larger Phase 2 and Phase 3 trials, along with regulatory approvals and commercialization success, are critical. The company also faces risks related to financing and competition. Therefore, a 'hold' recommendation is prudent, pending more definitive data and market developments.

Keywords

Forte Biosciences, FB102, Vitiligo, Phase 1b Study, Clinical Trial Results, Autoimmune Disease, Dermatology, FVASI, Immunomodulation, NASDAQ: FBRX, Biopharmaceutical